B cell

CytoTronics Reveals Pixel System to Monitor Live Cell Function at an Unprecedented Scale for Cell Biology Applications

Retrieved on: 
Monday, February 5, 2024

Pixel assesses live cell function at single-cell resolution, allowing scientists to simultaneously monitor cell viability, morphology, electrophysiology, metabolism, and more while generating electrical ‘images’ with single-cell spatial resolution.

Key Points: 
  • Pixel assesses live cell function at single-cell resolution, allowing scientists to simultaneously monitor cell viability, morphology, electrophysiology, metabolism, and more while generating electrical ‘images’ with single-cell spatial resolution.
  • Pixel delivers simultaneous multi-modal, high-resolution readouts in 96- or 384-well plates, enabling cell monitoring and data collection at unprecedented scale.
  • It’s widely applicable for in vitro cell biology applications including drug discovery, from target validation to toxicology screening.”
    CytoTronics’ early-access program for Pixel Primo empowers cell biologists to unlock applications that were previously inaccessible.
  • The early-access program includes applications for endothelial and epithelial cells, cancer cell biology, mechanism of action/toxicology, stem cell biology, cardiac function, and neural function.

Takara Bio’s First-to-Market Large-Scale Single-Cell NGS Profiling Technologies Poised to Revolutionize Biomarker Discovery

Retrieved on: 
Monday, February 5, 2024

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced plans to launch two critical solutions for oncology research.

Key Points: 
  • Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced plans to launch two critical solutions for oncology research.
  • The Shasta™ Total RNA-Seq Kit will detect splicing isoforms, gene fusions, and non-polyadenylated RNAs through full-length transcriptome profiling of up to 100,000 single cells per run.
  • “Our new kits will break the limits of current methods to enable true biological discovery,” said Carol Lou, President & CEO of Takara Bio USA.
  • With the new Shasta™ technologies, Takara Bio will introduce first-to-market high-scale solutions that can pick up important genetic events other technologies miss.

Scale Biosciences Unveils Platform for Dramatic Scaling of Single-Cell Experiments and Announces Partnerships to Drive Ease of Use and Enable New Biological Insights

Retrieved on: 
Monday, February 5, 2024

This technology will form the basis for future ScaleBio innovation and product development.

Key Points: 
  • This technology will form the basis for future ScaleBio innovation and product development.
  • “As we look to the future, we are focused on enabling dramatic scaling of single cell-based experiments with higher throughputs across a wider range of parameters and applications,” said Giovanna Prout, CEO of ScaleBio.
  • At AGBT, the companies will share combined datasets of high-resolution data from mouse brain tissue sections generated using their respective technologies.
  • ScaleBio also has a partnership with Basepair to offer the ScaleBio Seq Suite on the Basepair platform.

10x Genomics to Showcase New Cutting-Edge Technologies and Highlight Innovation Roadmap at 2024 AGBT General Meeting

Retrieved on: 
Monday, February 5, 2024

PLEASANTON, Calif., Feb. 5, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a series of new products and technology demonstrations that will be presented at the 2024 Advances in Genome Biology and Technology (AGBT) General Meeting this week in Orlando, Florida.

Key Points: 
  • "The new products we have planned for 2024 will take 10x to the next level, as we deliver game-changing new technologies that will redefine the Visium, Xenium and Chromium platforms," said Ben Hindson, Co-founder and Chief Scientific Officer of 10x Genomics.
  • 10x Genomics will host a workshop at AGBT on Wednesday, February 7, at 1:10 p.m.
  • At AGBT, 10x Genomics will unveil new products, features and protocols designed to enable researchers with improved and more cost effective single cell workflows.
  • Throughout AGBT, 10x Genomics will demonstrate the use of its platforms to generate groundbreaking biological insights:
    Sponsor Workshop: Mind blowing science enabled by industry-leading single cell & spatial technologies (February 7, 2024).

Meso Numismatics Increases 2023 Sales By 50% Year Over Year and Announces 2024 Forecast and Outlook

Retrieved on: 
Wednesday, January 31, 2024

Sales were derived from its 4 main channels, Training, Product sales, Equipment sales and Patient procedures.

Key Points: 
  • Sales were derived from its 4 main channels, Training, Product sales, Equipment sales and Patient procedures.
  • The Cancun clinic is currently active and is finalizing its full build out, which will double its footprint by the end of February.
  • The Company is in the process of building out a clinic in Dubai that will offer similar procedures to those in the Cancun location.
  • "We are excited to announce our significant growth across multiple channels, showcasing the strength and diversity of our business.

BioSkryb Genomics to Highlight Power of Next Generation Single-Cell Technology at AGBT 2024

Retrieved on: 
Tuesday, January 30, 2024

As a Bronze Sponsor, BioSkryb will also host a workshop and networking event at the meeting.

Key Points: 
  • As a Bronze Sponsor, BioSkryb will also host a workshop and networking event at the meeting.
  • “Our industry-first next generation single-cell technology offers the most comprehensive view of the integrated genome, transcriptome, and targeted proteins from each cell in a single workflow, and we are thrilled to highlight novel applications of our platforms at AGBT,” said Suresh Pisharody, CEO, BioSkryb.
  • BioSkryb’s events at AGBT 2024 are as follows:
    Jay A.A. West, Ph.D., Co-Founder & CTO, BioSkryb Genomics advances multiomics and highly accurate single-cell analysis with the next generation of single-cell technology.
  • Join BioSkryb and AGBT attendees to mingle with genomics and multiomics thought leaders over top-shelf bourbon selections and gourmet bacon-themed appetizers.

Grant Awarded to Develop Gastric Cancer Vaccine to Prevent Relapse After Surgery

Retrieved on: 
Thursday, February 1, 2024

Gastric cancer is the fourth leading cause of cancer mortality worldwide with mean life expectancy after standard therapy of 12 to 15 months.

Key Points: 
  • Gastric cancer is the fourth leading cause of cancer mortality worldwide with mean life expectancy after standard therapy of 12 to 15 months.
  • Avigan and his team hypothesize that a cancer vaccine targeting gastric cancer can help to train the immune system to eradicate tumor cells throughout the body and prevent disease relapse after surgery.
  • In the present study, they will examine whether designing this type of vaccine against gastric cancer will be effective in generating an immune response directed against gastric cancer cells.
  • They will use a novel approach to generating the vaccine to culture cancer cells outside the body as a part of vaccine production.

Dr. Gail K. Naughton, Ph.D., MBA, World Renowned Authority and Pioneer in Regenerative Medicine Named Science Advisor and to Board of Directors of Michal Morrison Inc.

Retrieved on: 
Thursday, February 1, 2024

βSTEM6 is the result of two decades of research in regenerative medicine and recent advances in stem cell science.

Key Points: 
  • βSTEM6 is the result of two decades of research in regenerative medicine and recent advances in stem cell science.
  • Dr. Naughton, a global leader in regenerative medicine for the past 35 years, has successfully developed significant cell-based therapeutics and bioengineered tissue technologies throughout her career.
  • "I am honored to join the scientists and the board at Michal Morrison Inc.
  • Michal Morrison Inc. has been honored by the beauty industry for its innovative technology and exquisite brand design.

Can the bugs in our guts help us manage inflammation?

Retrieved on: 
Tuesday, January 30, 2024

CINCINNATI, Jan. 30, 2024 /PRNewswire/ -- Imagine a day when people can enjoy snacking on foods designed to "re-calibrate" their microbiomes—that vast population of friendly bacteria living in our intestines—in order to promote a healthy immune system and decrease infections or chronic inflammation.

Key Points: 
  • Scientists have studied the intestine for many years, but even now they are learning surprising details about how it works.
  • "This study shows that the microbiota—and products made by the microbiota—can dynamically control immune responses in the gut," Alenghat says.
  • The research examines a reaction called type 2 immunity that occurs with chronic inflammatory conditions such as allergy and asthma.
  • Until now, it was not clear if nor how the gut microbiome impacts tuft cells.

Orphan designation: 5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride Treatment of adrenoleukodystrophy, 18/11/2016 Positive

Retrieved on: 
Sunday, February 4, 2024

Orphan designation: 5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride Treatment of adrenoleukodystrophy, 18/11/2016 Positive

Key Points: 


Orphan designation: 5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride Treatment of adrenoleukodystrophy, 18/11/2016 Positive